Placebo + Etripamil
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Jan 1, 2027 → Jan 1, 2030
NCT ID
NCT06716021About Placebo + Etripamil
Placebo + Etripamil is a phase 3 stage product being developed by Milestone Pharmaceuticals for Atrial Fibrillation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06716021. Target conditions include Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06716021 | Phase 3 | Recruiting |
Competing Products
20 competing products in Atrial Fibrillation